Modus Therapeutics submits patent application for sevuparin in kidney disease

pharmafile | January 23, 2023 | News story | Business Services  

STOCKHOLM, SWEDEN – 23 January 2023: Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet medical needs, announces that it has submitted a patent application claiming the use of sevuparin, its lead asset, for the treatment of kidney disease.


The patent application is based on novel preclinical work that was undertaken in an established kidney disease animal model during an academic collaboration project. A granted patent would provide patent protection until at least 2043.


Sevuparin is a proprietary compound of Modus Therapeutics, currently being evaluated in Phase 1 clinical trials as a potential treatment for sepsis and septic shock, as well as for severe malaria in children.


John Öhd, CEO of Modus Therapeutics, said: “Sevuparin is already in development as a potential new treatment for sepsis and septic shock. In addition, we are actively evaluating new avenues for development and commercialisation of our key asset, as well as continuously developing its patent portfolio in parallel. While the patent application is a tangible result of these efforts, it also demonstrates Modus´ ability to successfully collaborate internationally with leading academic institutions.”


For more information on Modus Therapeutics, please contact:

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97



Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Phone: +46 11 32 30 732



About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company’s focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at


Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Related Content

No items found

Latest content